On November 29, 2016, Aegerion Pharmaceuticals, Inc. completed its merger with QLT Inc. in which Aegerion is now an indirect wholly-owned subsidiary of QLT. In conjunction with the merger, QLT changed its name to Novelion Therapeutics Inc. Novelion is listed on NASDAQ and the Toronto Stock Exchange.

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases.

Gowling WLG acted as Canadian counsel to Aegerion with a team led by Henry Harris, which included Filomena Frisina, Paul Carenza, Ian Macdonald and Mariam Al-Shikarchy.